Careers Join our team Aquestive offers challenging and rewarding career opportunities for colleagues who share in our passion to improve the lives of patients and caregivers. We believe that engaged colleagues are a critical factor in our success.

2020-10-05

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Theravance Biopharma is a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering and advancing novel medicines. Life at GRAIL. GRAIL is an innovation-driven company where diversity, inclusion, and equity are critical drivers to our success. We embrace talent from all backgrounds, seek out diverse perspectives, facilitate and invite open and authentic conversations by promoting ownership and accountability. careers At Allogene, you'll find an experienced, high-performance, and growing team of employees whose sole focus is to transform the treatment of cancer. Our deep pipeline of innovative AlloCAR T™ therapies is based on an allogeneic platform enabled by validated gene editing and advanced proprietary cell-manufacturing technologies.

GRAIL is an innovation-driven company where diversity, inclusion, and equity are critical drivers to our success. We embrace talent from all backgrounds, seek out diverse perspectives, facilitate and invite open and authentic conversations by promoting ownership and accountability. Together. We’re a dynamic company, with a bold vision and bright future. We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

MYOKARDIA INC, 1,85 About us About us Contact us Contact us Careers Careers Investor relations Investor relations Press centre Press centre Terms

Contact 1 Tower Pl, 9th Floor South San Francisco, CA 94080 . 415-287-2300 415-287-2450 (fax) +1-888-255-6627

MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing Bristol-Myers Squibb is acquiring the Californian drugmaker MyoKardia for $13.1bn to expand its portfolio of cardiovascular drugs. The New York-based pharmaceutical company said it had agreed to 2020-10-05 · Bristol Myers Squibb Begins a $13.1 Billion Purchase of MyoKardia MyoKardia, Inc. (MYOK) Q2 2020 Earnings Call Transcript Why MyoKardia Shares Rose 62.8% in May Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded 2014-09-17 · PARIS and SOUTH SAN FRANCISCO, Calif., Sept.

careers At Allogene, you'll find an experienced, high-performance, and growing team of employees whose sole focus is to transform the treatment of cancer. Our deep pipeline of innovative AlloCAR T™ therapies is based on an allogeneic platform enabled by validated gene editing and advanced proprietary cell-manufacturing technologies. Join Our Team. We seek highly motivated professionals to join our team. We invite you to schedule a visit through Human Resources to learn more about our company and see our current open job postings below.
Kor malmo

Sr. Scientist, Process Chemistry.

“We want to change the world for people with cardiovascular disease by taking a patient-focused, scientifically driven approach,” Tassos Gianakakos, MyoKardia’s CEO, told BioSpace. MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing Bristol-Myers Squibb is acquiring the Californian drugmaker MyoKardia for $13.1bn to expand its portfolio of cardiovascular drugs.
Centerpartiet ekonomisk politik

2020-07-06 · BRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary.

ET. BRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today … Find 0 available jobs at MyoKardia with Ladders. Join Ladders to find the latest jobs at MyoKardia and get noticed by over 90,000 recruiters. 2020-03-30 2015-02-19 MyoKardia is currently preparing a New Drug Application (NDA) for mavacamten, with plans to submit to the FDA in the first quarter of 2021. About HCM Hypertrophic cardiomyopathy (HCM) is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in 2020-10-05 2020-07-06 Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY).

5 Feb 2016 First Release Notification. Science Careers Job Seeker. Country include but are not limited to news, career information, & upcoming events.

First Name* First name MyoKardia is headquartered in South San Francisco, CA and has 2 office locations across 1 country. See the full list at Craft. MyoKardia has 235 employees across 2 locations. See insights on MyoKardia including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry.

Mavacamten was to be effective in a pivotal Phase 3 clinical trial in patients with symptomatic obstructive HCM. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. At AHA Scientific Sessions 2020, phase 3 data in hypertrophic cardiomyopathy (HCM) will be presented. MyoKardia is a pioneering biopharmaceutical company that is leading the way in targeted therapies for underserved cardiovascular diseases. 2020-10-05 Tufts University Career Center LinkedIn Instagram YouTube Dowling Hall Suite 740 (9am-5pm) 419 Boston Avenue Medford, MA 02155 (617) 627-3299 careercenter@tufts.edu Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry.